移植物和患者的生存率与ANCA相关性血管炎的患者相比，那些在非糖尿病患者中观察到。
Graft and patient survival rates among patients with ANCA-associated vasculitis are comparable to those observed in nondiabetic patients.
用利妥昔单抗治疗难治性ANCA相关性血管炎时，其缓解率可达80%到90%，可能比环磷酰胺疗法更安全。
Treatment with rituximab has led to remission rates of 80 to 90% among patients with refractory ANCA-associated vasculitis and may be safer than cyclophosphamide regimens.
ANCA相关性血管炎患者的死亡率不断提高，我们的能力，以应对在这个患者人群肾功能衰竭的后果变得极为重要。
As the mortality of patients with ANCA-associated vasculitis continues to improve, our ability to address the consequences of renal failure in this patient population becomes Paramount.
方法对20例确诊为ANCA相关性小血管炎患者的临床资料进行总结分析。
Methods Make a definite diagnosis of, summarize and analyze to 20 for ANCA associated systemic vasculitis inflammation clinical materials of patient.
与静脉应用甲基强的松龙相比，血浆置换使发病时伴有肾衰的ANCA相关性系统性血管炎患者肾脏恢复比例增加。
Plasma exchange increased the rate of renal recovery in ANCA-associated systemic vasculitis that presented with renal failure when compared with intravenous methylprednisolone.
与静脉应用甲基强的松龙相比，血浆置换使发病时伴有肾衰的ANCA相关性系统性血管炎患者肾脏恢复比例增加。
Plasma exchange increased the rate of renal recovery in ANCA-associated systemic vasculitis that presented with renal failure when compared with intravenous methylprednisolone.
应用推荐